Premium
Time course of serum hepatitis C virus‐RNA during chronic hepatitis C treatment accurately predicts the type of response
Author(s) -
Calleja J. L.,
Albillos A.,
Rossi I.,
Moreno R.,
Domper F.,
MartÍnez J. L.,
EscartÍn P.
Publication year - 2001
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2001.00921.x
Subject(s) - ribavirin , medicine , interferon , combination therapy , hepatitis c virus , gastroenterology , alanine transaminase , alpha interferon , viral load , hepatitis c , hepatitis , alanine aminotransferase , immunology , virus
Aim: To establish the value of alanine aminotransferase normalization and hepatitis C virus‐RNA clearance as predictors of sustained virological response in naïve and relapser chronic hepatitis C patients on mono or combination therapy. Methods: A total of 282 hepatitis C patients were studied: 98 naïves on interferon, and 64 naïves and 75 relapsers on interferon plus oral ribavirin; 45 patients were excluded. Drugs were administered at standard doses for 12 months. Alanine aminotransferase and hepatitis C virus‐RNA were determined at baseline and at weeks 4, 12, 24, 48, and at 72 and 96 weeks after completion of therapy. Results: The rate of sustained response was greater ( P < 0.05) in naïves and relapsers on combination therapy (33% and 48%, respectively) than in naïves on interferon alone (16%). Hepatitis C virus‐RNA significantly decreased from baseline by week 4 in naïves on interferon and relapsers on combination therapy and by week 12 in naïves on combination therapy. Alanine aminotransferase levels paralleled viremic load in naïves on interferon, yet in patients on combination therapy, alanine aminotransferase normalized independently of the virological response. During treatment, the main factor associated with sustained response was hepatitis C virus‐RNA clearance by week 4 in naïves on interferon and relapsers on combination therapy, and by week 24 in naïves on combination therapy. Conclusion: Clearance of viraemia constitutes the best predictor of a sustained response to therapy, but needs to be measured at patient‐specific times.